J&J in talks to acquire Protagonist Therapeutics
The acquisition would grant J&J access to rusfertide, which has demonstrated promise in late-stage trials for polycythaemia vera.
Drug Development
FDA approves Teva and Medincell’s bipolar I disorder treatment
FDA ‘green list’ flagging illegal GLP-1RA compounders is long overdue
Arthrosi gains $153m for development of gout therapy
FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery
China accounts for one-fifth of global drugs in development
Affinia raises $40m for gene therapy development
Oragenics partners Receptor.AI for brain health candidate portfolio
